Source comparison
Conclusion: Dual vs Single Receptor Cardiac Biology
Hexarelin and Ipamorelin represent a uniquely powerful research pair for dissecting cardiac GHS-R1a biology. Ipamorelin, as the most selective GHS-R1a agonist, provides the definitive GHS-R1a-only cardiac phenotype — reducing infarct size −33%, attenuating pos
This comparison does not assign a generated winner or score.
- Hexarelin and Ipamorelin represent a uniquely powerful research pair for dissecting cardiac GHS-R1a biology. Ipamorelin, as the most selective GHS-R1a agonist, provides the definitive GHS-R1a-only cardiac phenotype — reducing infarct size −33%, attenuating post-MI fibrosis −26%, and improving LVEF +12–16% without HPA activation or CD36 engagement. Hexarelin, adding CD36 → Src → FAK secondary signalling, produces superior outcomes across all parameters — infarct −48%, fibrosis −47%, LVEF +18–22% — with the additional CD36-mediated lipotoxic FA accumulation reduction providing a unique ischaemic metabolic protection mechanism. The Hexarelin/Ipamorelin comparison is the only experimental design that can cleanly attribute cardiac protection biology to GHS-R1a versus CD36 — making it an essential tool in cardiac peptide research pharmacology.
- William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.